Remus Pharmaceuticals Limited vs Zydus Lifesciences Limited

A side-by-side comparison of Remus Pharmaceuticals Limited (REMUS) and Zydus Lifesciences Limited (ZYDUSLIFE) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, Zydus Lifesciences Limited leads REMUS vs ZYDUSLIFE on 10 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation13
  • Profitability04
  • Growth20
  • Size & financial health13
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

ZYDUSLIFE takes 3/4

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

27.80
P/E ratio
22.42
3.00
P/B ratio
4.11
0.06%
Dividend yield
0.09%
₹36.55
EPS
₹50.09

Profitability

ZYDUSLIFE takes 4/4

How efficiently each company turns capital and sales into profit. Higher is better.

10.54%
Return on equity
18.59%
16.04%
Return on capital
18.07%
6.64%
EBITDA margin
31.22%
5.41%
Net margin
18.87%

Growth

REMUS takes 2/2

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

166.64%
Revenue CAGR (3Y)
16.35%
75.78%
Profit CAGR (3Y)
34.80%

Size & financial health

ZYDUSLIFE takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹1,181 Cr
Market cap
₹1.12L Cr
₹854 Cr
Revenue
₹27,148 Cr
₹46 Cr
Net profit
₹5,124 Cr
0.08
Debt / equity
0.46
Remus Pharmaceuticals Limited
  • + ["Company has delivered good profit growth of 113.9% CAGR over last 5 years", "Company has a good return on equity (ROE) track record: 3 Years ROE 27.6%", "Company is almost debt free.", "Company has delivered good sales growth of 115.4% CAGR over last 5 years"]
  • − []
Zydus Lifesciences Limited
  • + ["Company has delivered good profit growth of 18.6% CAGR over last 5 years", "Company has a good return on equity (ROE) track record: 3 Years ROE 20.9%"]
  • − []
Remus Pharmaceuticals Limited full analysis Zydus Lifesciences Limited full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.